Table 1 Clinical features of VKH patients and healthy controls enrolled in the study
Clinical features | First Stage | Second stage | Total | |||
|---|---|---|---|---|---|---|
VKH (n = 384) | % | VKH (n = 382) | % | VKH (n = 766) | % | |
Age, median (IQR) | 44 (32–53) |  | 39.5 (29–47) |  | 42 (31–50) |  |
 Male | 199 | 51.8 | 201 | 52.6 | 400 | 52.2 |
 Female | 185 | 48.2 | 181 | 47.4 | 366 | 47.8 |
 Uveitis | 384 | 100.0 | 382 | 100.0 | 764 | 100.0 |
Sunset glow fundus | 181 | 47.1 | 190 | 50.0 | 371 | 48.6 |
Headache | 193 | 50.3 | 175 | 46.1 | 368 | 48.2 |
 Tinnitus | 171 | 44.5 | 166 | 43.5 | 337 | 44.0 |
 Vitiligo | 39 | 10.2 | 51 | 13.4 | 90 | 11.8 |
 Alopecia | 106 | 27.6 | 128 | 33.7 | 234 | 30.6 |
 Poliosis | 102 | 26.6 | 114 | 30.0 | 216 | 28.3 |
 Dysacusia | 148 | 38.5 | 118 | 30.9 | 266 | 34.7 |
 Healthy controls | 384 |  | 525 |  | 909 |  |
Age, median (IQR) | 38 (31–46) |  | 40 (33–46) |  | 39 (32–46) |  |
 Male | 183 | 47.7 | 267 | 50.9 | 450 | 49.5 |
 Female | 201 | 52.3 | 258 | 49.1 | 459 | 50.5 |